Amorepacific is positioning AESTURA and ILLIYOON as major global growth brands rather than Korea-only derma labels.
At its 2026 Investor Day, the company said it plans to build a KRW 1 trillion derma-beauty business by BY30, led by AESTURA and ILLIYOON.
For shoppers, the more interesting question is what sits behind that target.
By the numbers
KRW 1 trillion - Amorepacific's derma-beauty revenue target by BY30, the business year running from July 2029 through June 2030
36 countries - Markets where AESTURA has launched over the past three years
4x+ - Increase in AESTURA's global revenue last year, according to Amorepacific
KRW 15 trillion - Amorepacific's broader company revenue target for BY35
AESTURA is the more internationalized brand today
Amorepacific says AESTURA has expanded into 36 countries over the past three years.
Its global growth is centered on the ATOBARRIER365 line, which the company describes as the brand's flagship franchise.
That makes AESTURA useful to watch because it shows how a Korean derma brand moves from domestic pharmacy and beauty-channel credibility into global beauty retail.
ILLIYOON plays a different role
ILLIYOON is positioned around sensitive-skin and body-moisturizing products with broad everyday use.
Amorepacific is using AESTURA and ILLIYOON together rather than treating them as interchangeable brands.
For SEEN IN KOREA, that creates a better consumer story than simply reporting a corporate revenue target.
The useful comparison is:
AESTURA - more clinical, facial-skincare-led derma positioning
ILLIYOON - broader sensitive-skin and body-care positioning
Why this matters
K-beauty's next global growth phase is not only about viral makeup or sunscreen.
Large Korean beauty groups are investing heavily in derma and clinical skincare as long-term global categories.
The next useful SEEN IN KOREA article should compare the actual hero products, Korean prices, global prices and intended use cases - starting with ATOBARRIER365 and ILLIYOON's core ceramide products.